Health Alerts, Advisories, Notifications, and Updates

 

Surveillance

  • Case Definition: A positive culture of Candida auris or Candida haemulonii (Candida auris is frequently misidentified as Candida haemulonii) from any body site including, but not limited to blood, wound, skin, ear, urine, rectum, and respiratory tract, collected for diagnostic purposes or surveillance/screening purposes.
  • PDPH Candida auris Data
  • National Surveillance Data on Candida auris


Vaccine Information

  • There is currently no vaccine to prevent Candida auris.


Diagnostics and Treatment

  • Candida auris infection is diagnosed through a culture of the affected body site. Candida auris can be frequently misidentified when using traditional phenotypic methods for yeast identification such as VITEK 2 YST, API 20C, BD Phoenix yeast identification system, and MicroScan. Common misidentifications are listed here. If any of these species are identified, or if species identity cannot be determined, further characterization using appropriate methodology should be sought. Please email or call the HAI/AR team at (215) 685-4501 for assistance with this.
  • Candida auris is often resistant to many antifungal drugs, although some infections can be treated with antifungal medicines. Providers should order antifungal susceptibility testing to determine the appropriate drug for treatment.
  • Candida auris colonization is primarily identified through a culture or a PCR based test from a swab collected from the axilla and/or groin. CDC does not recommend treatment of Candida auris identified from noninvasive body sites (such as respiratory tract, urine, and skin colonization) when there is no evidence of infection.
  • Report all cases (colonization or infection) to PDPH immediately and retain Candida auris isolates for one month following identification.  PDPH will follow up to coordinate further testing.
  • CDC Laboratory Protocol for Detecting Candida auris
  • CDC Antifungal Susceptibility Testing & Interpretation
  • CDC Treatment and Management of Infections and Colonization with Candida auris
  • Screening for Candida auris Colonization


Reporting to PDPH

  • Report all C.auris cases (colonization or infection) to the Philadelphia Department of Public Health by calling 215-685-6748 within 24 hours. Complete the Candida auris Report Form and fax to 215-238-6947 after reporting the case by phone.

  • Drug Resistant Organism Reporting Requirements: Frequently Asked Questions


Health Education Materials

 

Links and Resources


Guidelines for Management and Control

CDC GUIDELINES:

HOSPITALIZED PATIENTS: 

  • Candida auris patients shall be placed on contact precautions and in a private room for the duration of all current and future healthcare stays.

  • Because patients may remain colonized for more than one year, do not discontinue precautions when the infection clears. There is not enough evidence to make a firm recommendation about when to discontinue use of Contact Precautions for infected or colonized patients.

  • Inter-facility transfer: Prior to patient transfer, the transferring facility should notify the receiving facility of the Candida auris colonization or infection.

LONG TERM CARE FACILITY RESIDENTS:

  • Candida auris patients shall be placed on contact precautions or enhanced standard precautions and placed in a private room, if available, for the duration of all current and future healthcare stays.
  • If patients cannot be placed in a private room, in room isolation precautions should be implemented.
  • Because patients may remain colonized for more than one year, do not discontinue precautions when the infection clears or antifungal course is completed.
  • Inter-facility transfer: Prior to patient transfer, the transferring facility should notify the receiving facility of the C. auris colonization or infection.

DISINFECTION GUIDANCE:  

  • Candida auris can persist on surfaces in healthcare environments. Meticulous cleaning and disinfection of both patient rooms and mobile equipment is necessary to reduce the risk of transmission.
  • Until further information is available for Candida auris, CDC recommends use of an Environmental Protection Agency (EPA)-registered hospital-grade (LIST K) disinfectant effective against Clostridioides difficile spores. It is important to follow all manufacturers’ directions for use of the surface disinfectant, including applying the product for the correct contact time.
  • Solution with 10% bleach should be made fresh daily. 
  • Reusable equipment should be dedicated to the colonized or infected patient whenever possible.
  • Shared reusable medical equipment should be disinfected immediately after use. 
  • Daily disinfection, with products appropriate for Candida auris, that includes areas in close proximity to the patient, high-touch surfaces in the room, as well as surfaces around sinks and toilets.
  • Immediate cleaning and disinfection of equipment or surfaces contaminated with blood, serum, urine, purulent discharges, feces, and other bodily fluids or infectious materials.
  • Terminal cleaning shall consist of thorough wet cleaning and disinfection. Specific products should be utilized based on the identified organism.